Literature DB >> 3874025

Family distribution of anti-F(ab')2 antibodies in relatives of patients with systemic lupus erythematosus.

F Silvestris, R P Searles, A D Bankhurst, R C Williams.   

Abstract

Recently we reported an inverse relationship between the levels of anti-F(ab')2 antibodies and disease activity in systemic lupus erythematosus (SLE). The present study focused on anti-F(ab')2 antibodies in unaffected relatives of SLE patients. Sixty sera from first degree family members from 11 SLE families and 49 sera from 8 control families were studied. Percentage of SLE family members with anti-DNA antibodies (15%) was higher than than control family sera (8%, P less than 0.05). Anti-F(ab')2 antibodies were measured using ELISA assays. The SLE family sera had higher amounts of anti-F(ab')2 antibodies than the normal control family group (P = 0.0051). In an effort to determine if anti-F(ab')2 antibodies found in high titres in the sera of some SLE family members had specificity for the F(ab')2 fragment of anti-DNA antibodies of the SLE relative patients, DNA-anti-DNA inhibition experiments were performed using anti-F(ab')2 prepared from the relative in parallel with anti-F(ab')2 prepared from normal controls with equivalent high titres of serum anti-F(ab')2. Inhibition exhibited by anti-F(ab')2 of first degree relatives was higher than that obtained from control normal donors (P less than 0.02). Such differences in inhibition were not recorded using a control tetanus toxoid-anti-tetanus toxoid assay. In direct binding ELISA experiments, peroxidase-conjugated anti-F(ab')2 antibodies from the same first degree relative showed high relative specificity against purified anti-DNA antibodies of his SLE proband when compared to those obtained against different anti-DNA antibodies isolated from unrelated SLE patients (P less than 0.001). Such a substantial difference was not observed in parallel experiments using peroxidase conjugated anti-F(ab')2 antibodies from normal controls unrelated to SLE subjects.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3874025      PMCID: PMC1577027     

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  26 in total

1.  Separation of univalent fragments from the bivalent rabbit antibody molecule by reduction of disulfide bonds.

Authors:  A NISONOFF; F C WISSLER; L N LIPMAN; D L WOERNLEY
Journal:  Arch Biochem Biophys       Date:  1960-08       Impact factor: 4.013

2.  Lymphocytotoxic antibodies in family members of patients with systemic lupus erythematosus.

Authors:  R J DeHoratius; R P Messner
Journal:  J Clin Invest       Date:  1975-06       Impact factor: 14.808

3.  B-lymphocyte alloantigens associated with systemic lupus erythematosus.

Authors:  J L Reinertsen; J H Klippel; A H Johnson; A D Steinberg; J L Decker; D L Mann
Journal:  N Engl J Med       Date:  1978-09-07       Impact factor: 91.245

4.  Familial chronic discoid lupus erythematosus and hypergammaglobulinemia.

Authors:  R C Gallo; D L Forde
Journal:  Arch Intern Med       Date:  1966-05

5.  Antilymphocyte antibodies in systemic lupus erythematosus patients and their relatives: reactivity with nonhuman lymphocytes.

Authors:  J I Allen; R P Searles; R P Messner; A D Bankhurst
Journal:  Clin Immunol Immunopathol       Date:  1978-03

6.  Towards a network theory of the immune system.

Authors:  N K Jerne
Journal:  Ann Immunol (Paris)       Date:  1974-01

7.  Anti-nucleic acid antibodies in systemic lupus erythematosus patients and their families. Incidence and correlation with lymphocytotoxic antibodies.

Authors:  R J DeHoratius; R Pillarisetty; R P Messner; N Talal
Journal:  J Clin Invest       Date:  1975-11       Impact factor: 14.808

8.  Immunoglobulin class of antilymphocyte antibodies in systemic lupus erythematosus patients and their families.

Authors:  R P Searles; G Husby; P Messner
Journal:  Acta Pathol Microbiol Scand C       Date:  1977-12

Review 9.  Studies in familial systemic lupus erythematosus.

Authors:  F C Arnett; L E Shulman
Journal:  Medicine (Baltimore)       Date:  1976-07       Impact factor: 1.889

10.  Histocompatibility (HL-A) antigens and lymphocytotoxic antibodies in systemic lupus erythematosus (SLE).

Authors:  K M Nies; J C Brown; E L Dubois; F P Quismorio; G J Friou; P I Terasaki
Journal:  Arthritis Rheum       Date:  1974 Jul-Aug
View more
  7 in total

1.  Anti-DNA idiotype- and anti-idiotype-specific T cell responses in patients with systemic lupus erythematosus and their first-degree relatives.

Authors:  S Mendlovic; R Segal; Y Shoenfeld; E Mozes
Journal:  Clin Exp Immunol       Date:  1990-12       Impact factor: 4.330

Review 2.  The idiotype-antiidiotype network in human autoimmunity.

Authors:  N I Abdou
Journal:  J Clin Immunol       Date:  1985-11       Impact factor: 8.317

3.  Antiidiotypic antibodies against anti-DNA antibodies in sera of families of lupus patients.

Authors:  N I Abdou; R Suenaga; M Hatfield; M Evans; K M Hassanein
Journal:  J Clin Immunol       Date:  1989-01       Impact factor: 8.317

4.  Anti-idiotypic antibody against anti-DNA in sera of laboratory personnel exposed to lupus sera or nucleic acids.

Authors:  M Hatfield; M Evans; R Suenaga; K M Hassanein; N I Abdou
Journal:  Clin Exp Immunol       Date:  1987-10       Impact factor: 4.330

5.  Molecular localization of human IgG anti-F(ab')2 reactivity with variable- and constant-region lambda light-chain epitopes.

Authors:  R C Williams; C C Malone; F Silvestris; A Solomon
Journal:  J Clin Immunol       Date:  1995-11       Impact factor: 8.317

6.  Distribution of anti-F(ab')2 antibodies and the 16/6 idiotype in systemic lupus erythematosus (SLE) probands and kindreds.

Authors:  F Silvestris; R A Searles; R C Williams; M A Rodriguez; R S Schwartz
Journal:  J Clin Immunol       Date:  1989-11       Impact factor: 8.317

7.  Association between a T cell receptor restriction fragment length polymorphism and systemic lupus erythematosus.

Authors:  J G Tebib; J Alcocer-Varela; D Alarcon-Segovia; P H Schur
Journal:  J Clin Invest       Date:  1990-12       Impact factor: 14.808

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.